Talphera (TLPH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 22, 2026, with voting open until June 21, 2026 at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by June 8, 2026.
Voting can be completed online or virtually at the meeting.
Voting matters and shareholder proposals
Election of three directors: Marina Bozilenko, Joseph Todisco, and Mark Wan, with board recommending a vote for all.
Ratification of BPM LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve named executive officer compensation.
Approval of Amended and Restated 2020 Equity Incentive Plan.
Approval of Amended and Restated 2011 Employee Stock Purchase Plan.
Provision for other business to be addressed as may properly come before the meeting.
Board of directors and corporate governance
Board recommends all director nominees and all proposals for shareholder approval.
Latest events from Talphera
- Board recommends approval of all proposals, including director elections and plan amendments.TLPH
Proxy filing29 Apr 2026 - Niyad targets a major gap in anticoagulation for dialysis, with pivotal study completion expected in 2026.TLPH
Corporate presentation29 Apr 2026 - Resale registration for $4.1M in shares and warrants; acute care focus; no proceeds to issuer.TLPH
Registration filing25 Mar 2026 - 50% enrollment milestone reached in NEPHRO CRRT study, unlocking $4.1M financing tranche.TLPH
Q4 2025 & Investor Day23 Mar 2026 - Q2 net loss narrowed, $14M cash, NEPHRO study expanded, but more funding needed soon.TLPH
Q2 20241 Feb 2026 - Pivotal phase III trial of Niyad targets 2025 finish, with strong IP and market prospects.TLPH
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - NEPHRO CRRT trial advances, net loss is $3.4M, and $11.1M cash on hand; more funding needed.TLPH
Q3 202414 Jan 2026 - FDA-approved protocol changes and $14.8M financing support NEPHRO CRRT study completion.TLPH
Q4 202424 Dec 2025 - Resale registration for shares and warrants from a private placement; no new capital raised.TLPH
Registration Filing16 Dec 2025